Dana M. Chase, MD, FACOG, discusses the antibody-drug conjugate tisotumab vedotin including its mechanism of action, its accelerated approval for patients with recurrent cervical cancer and at least one prior line of therapy, and the management of toxicities such as neuropathy and pneumonitis.
Treatment with intermittent or continuous doses of relacorilant in combination with nab-paclitaxel resulted in an overall survival benefit compared with nab-paclitaxel monotherapy, but failed to demonstrate an improvement in progression-free survival in patients with recurrent, platinum-resistant ovarian cancer.
FDA Approves Expanded Indication for Merck s KEYTRUDA® in Locally Advanced Cutaneous Squamous Cell Carcinoma investingnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investingnews.com Daily Mail and Mail on Sunday newspapers.